Biolinq
The company's patch uses intradermal electrochemical sensors to monitor glucose levels and provide metabolic insights to individuals with type 2 diabetes not on insulin.
EarliTech Diagnostics secured $21.5 million, Manifold emerged with $15 million, and Beanstalk Benefits launched out of Redesign Health with $7.5 million.
Biolinq's new funding was led by JDRF T1D Fund, Aphelion Capital and LifeSci Venture Partners.